Abstract: AIM:To compare the outcomes of paclitaxel-loaded microporous stents and imported sirolimus-eluting stents in the treatment of patients undergoing percutaneous coronary intervention (PCI). METHODS: Seventy-three patients who underwent PCI were randomly divided into two groups: 35 patients with paclitaxel-loaded microporous stent (paclitaxel stents) and 38 patients with imported sirolimus-eluting stents (sirolimus group). Coronary artery angiography (CAG) was performed in all patients after a 6-month follow-up period. The incidence of major adverse cardiac events (MACEs) including cardiac death, myocardial infarction and target lesion revascularization and in-stent restenosis rate were compared. RESULTS: During a 6-month follow-up, there were no acute, subacute, or late stent thromboses, nonlethal myocardial infarction or cardiac deaths in the two groups. Differences in angina, in-stent restenosis and target lesion revascularization were not statistically significant between groups. CONCLUSION: Paclitaxel-loaded microporous stents have the same clinical effects and safety as imported sirolimus-eluting stents for coronary artery disease in clinical outcomes in the short- and medium-term. Moreover, the cost-effectiveness ratio of paclitaxel-loaded microporous stents is higher.